echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Corning Jerry Announces Phase II Clinical Data of KN046 Combined with Chemotherapy in the Treatment of Advanced NSCLC

    Corning Jerry Announces Phase II Clinical Data of KN046 Combined with Chemotherapy in the Treatment of Advanced NSCLC

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 7, 2021, Corning Jereh Biopharmaceuticals announced that it will announce the PD-L1/CTLA-4 bispecific antibody KN046 combined with platinum chemotherapy at the 2021 American Society of Clinical Oncology (ASCO 2021) annual meeting in the form of a poster Phase II clinical study data of patients with advanced non-small cell lung cancer (study number: KN046-202)


    KN046 combined with platinum-based chemotherapy showed good tolerability and effectiveness in first-line advanced non-small cell lung cancer; the 12-month and 15-month survival rate (OS rate) were 74.


    KN046-202 (NCT04054531) is a phase II, open, multi-center clinical study designed to evaluate the efficacy, safety and tolerability of KN046 combined with platinum-based chemotherapy in patients with advanced non-small cell lung cancer.


    As of January 19, 2021, a total of 87 patients with advanced non-small cell lung cancer who have not received systemic treatment were enrolled, including 51 patients with non-squamous cell carcinoma and 36 patients with squamous cell carcinoma


    Among 81 patients with evaluable efficacy, the objective response rate (ORR) was 50.


    The median progression-free survival (mPFS) is 5.


    In terms of safety, 22 patients (25.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.